Zolpidem is a non-benzodiazepine 'Z-drug' hypnotic for short-term insomnia that acts selectively at the omega-1 GABA-A receptor. Although benzodiazepine-like in action, it is structurally distinct and is not detected by benzodiazepine immunoassays, so confirming its use requires targeted LC-MS/MS.1
Zolpidem misuse is not rare (about 807,000 people reported past-year misuse in a 2020 national survey), and it can cause complex sleep behaviors such as sleepwalking and sleep-driving. Because it is invisible to benzodiazepine screens, both adherence and misuse require targeted testing.2
Zolpidem is not on benzodiazepine immunoassays; targeted LC-MS/MS is required. Urine testing measures the inactive carboxy metabolite, which appears at higher concentrations than the parent, whereas oral fluid measures the parent and may be metabolite-negative.3 Match the matrix to the analyte when interpreting results.
Confirms recent use. The carboxy metabolite (urine) or parent (oral fluid) indicates use within the window.
Matrix determines the analyte. Urine shows the metabolite; oral fluid shows the parent and may be metabolite-negative.3
Not a benzodiazepine result. Zolpidem detection is independent of the benzodiazepine panel.
Short window. Detection is about 1 to 2 days; a negative may reflect timing or PRN use.
Benzo screen is irrelevant. A negative benzodiazepine immunoassay says nothing about zolpidem.
Timing and cutoff. Absence may reflect timing of last use or levels below the cutoff.
Zolpidem analytes measured on definitive testing.
| Metabolite | Clinical Significance |
|---|---|
| Zolpidem (parent) | Short half-life (~3 h); the oral-fluid target. |
| Zolpidem carboxylic acid | Inactive major metabolite; the urine target, higher than parent. |